From Wikipedia, the free encyclopedia
Chemical compound
Alalevonadifloxacin
Trade names Emrok O
Routes of administration Oral
Legal status
(12S )-8-[4-[(2S )-2-Aminopropanoyl]oxypiperidin-1-yl]-7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13 ]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
CAS Number
PubChem
CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Formula C 22 H 26 F N 3 O 5
Molar mass 431.464 g·mol−1 3D model (
JSmol )
C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)OC(=O)[C@H](C)N)F)C(=O)O
InChI=InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
Key:OUXXDXXQNWKOIF-RYUDHWBXSA-N
Alalevonadifloxacin (trade name Emrok O ) is an antibiotic of the
fluoroquinolone class.
[1] It is a
prodrug of
levonadifloxacin with increased
oral bioavailability .
[2] In India, it is approved for the treatment of infections with
Gram-positive bacteria.
[3]
References
^ Saseedharan S, Dubey D, Singh RK, Zirpe K, Choudhuri AH, Mukherjee DN, et al. (2024).
"Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral)" . Indian Journal of Medical Microbiology . 47 : 100528.
doi :
10.1016/j.ijmmb.2024.100528 .
PMID
38228227 .
^ Bhawsar S, Kale R, Deshpande P, Yeole R, Bhagwat S, Patel M (December 2021). "Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection". Bioorganic & Medicinal Chemistry Letters . 54 : 128432.
doi :
10.1016/j.bmcl.2021.128432 .
PMID
34757217 .
^
"Alalevonadifloxacin" . AdisInsight . Springer Nature Switzerland AG.